Navigation Links
Efficacy Advantages and Long-Term Cost Savings Will Help Optimize Reimbursement in the EU5 for Type 2 Diabetes Agents
Date:8/26/2013

BURLINGTON, Mass., Aug. 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that as the health technology assessment bar rises sharply across the EU5 (France, Germany, Italy, Spain and the United Kingdom), interviewed payers seek robust efficacy advantages over the right comparators and clear demonstration of potential for downstream cost savings in exchange for optimal reimbursement of type 2 diabetes therapies. As type 2 diabetes becomes increasingly prevalent in Western markets, the cost of related complications and comorbidities weighs heavily on tightening EU5 healthcare budgets. Payers report that novel agents that delay disease progression and show positive weight loss and cardiovascular outcomes data, ideally with detailed pharmacoeconomic analyses, will secure favorable market access conditions long term.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The new European Physician and Payer Forum report entitled Market Access Challenges Facing Newly Launched and Emerging Type 2 Diabetes Agents in the EU5: Physician Prescribing Perspectives and Payer Insights finds that at least three-quarters of surveyed EU5 endocrinologists, diabetologists and general practitioners (GPs) believe that, despite market crowding, unmet need remains for the DPP-IV inhibitor drug class, while at least two-thirds think likewise for the GLP-1 receptor agonists. Key unmet needs highlighted for the DPP-IV inhibitors include better reduction in HbA1c, and confirmation of disease-modifying effect, while—in addition to injection-free administration—positive cardiovascular outcomes data emerges as a primary preference for the GLP-1 analogues. Agents targeting these unmet needs should also help to address payer demands for downstream cost-savings, thus encouraging budget holders at all levels to think beyond the price tag as competition heightens among type 2 diabetes drug classes.    

However, the report also finds that as manufacturers strive for optimal pricing and reimbursement terms amid stringent HTA demands, they must be careful not to price themselves out of the market if they want to secure maximum uptake of their brands. Price must be carefully balanced with uptake potential for optimal return on investment.

"One quarter of surveyed GPs in Germany do not currently prescribe GLP-1 analogues to more than half of their eligible type 2 diabetes patients due to the constraints of their indicative prescribing budgets, while around two thirds of survey respondents in Spain report that their ability to prescribe DPP-IV inhibitors and GLP-1 analogues is at least somewhat impacted by recently increased patient copay," said Decision Resources Senior Director Janie Cox, Ph.D. "As the EU5 countries continue to feel the force of the economic crisis, industry is challenged with maximizing profitability at competitive rather than premium prices."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Renal Dialysis Equipment Market to 2017- Lower Costs and Similar Efficacy Rates as Hemodialysis to Increase Adoption Rates of Peritoneal Dialysis
2. MedQIA unique CAD algorithm for Quantitation of lung involvement in diffuse lung disease used as treatment efficacy end point in study to be reported at the ERS Annual Conference in Vienna, Austria: September 1-5, 2012
3. Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
4. Sosei Group Corporation: Data at ERS Shows Efficacy of Once-daily COPD Portfolio Versus Comparators, Further Establishes Dual-bronchodilator QVA149
5. Optimization of Comparative Efficacy Trials
6. JAMA Study Demonstrates Efficacy of Life Technologies Lung Cancer Test in Detecting Early Metastases, Supports Screening for Lung Cancer
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
9. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
10. Lilly Discontinues Phase 3 Rheumatoid Arthritis Program for Tabalumab Based on Efficacy Results
11. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... 24, 2017 Today Stock-Callers.com have issued ... are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), Edwards ... SSH ). These companies are part of the Healthcare ... Thursday, March 23 rd , 2017, with the NYSE Health ... health care companies in the S&P 500 were down about ...
(Date:3/24/2017)... , March 23, 2017  Mirabilis Medical, a ... medical technology for non-invasive surgery, announced today CE ... for treatment of uterine fibroids throughout the European ... received approval from the US Food and Drug ... Mirabilis System in the United States.  The Mirabilis ...
(Date:3/23/2017)... Care, based in St. Joseph, Missouri , has selected AccuReg to ... located in 22 cities, and its flagship St. Joseph Medical Center. Mosaic ... health care to its patients, including the insurance, billing and collections processes. ... ... Care St. Joseph Medical Center ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... Texas ... which can be found at 9618 Huebner Road. The clinic is the group’s 7th ... Clinic Director, and Dr. Ali Higgins, PT, will provide care from the clinic, which ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... they are now offering treatments for sleep apnea and TMJ at their office. ... Sleep apnea , specifically the obstructive type, is increasingly being treated at dental ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of Serenity ... MD. Judy says, “I am passionate about sharing Reiki as a holistic, complementary ... and challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys ...
Breaking Medicine News(10 mins):